The ATTCK-20-03 trial serves as proof of principle regarding the ACTR approach that could potentially be used with other antibodies targeting other markers in other malignancies. Although the ACTR707 program has been discontinued, these results may support other programs in employing similar novel approaches of antibody-coupled T-cell activation.
1 year ago
P1 data • Journal • Combination therapy • IO biomarker
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • cyclophosphamide • fludarabine IV • ACTR707
ACTR707 is in clinical development in combination with rituximab (NCT03189836) or trastuzumab (NCT03680560)...Subjects receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine) for 3 days, followed by rituximab and a single dose of ACTR707... Data available from DL1 through DL3 of ACTR707+rituximab suggest that clinical responses can be achieved without severe T cell-mediated toxicities (eg, CRS and neurotoxicity) that have been reported with other autologous T-cell products. Dose escalation continues at a target dose of 80×106 ACTR+ T cells; enrollment in DL4 (n=6) was recently completed. Updated data, including identified correlates of clinical outcomes, will be presented for DL1 through DL4.
5 years ago
Clinical • P1 data • Combination therapy
|
CD8 (cluster of differentiation 8)
|
Herceptin (trastuzumab) • Rituxan (rituximab) • fludarabine IV • ACTR707